Bruce Booth Sells Shares of Kymera Therapeutics

Bruce Booth, an insider at Kymera Therapeutics, Inc. (NASDAQ:KYMR), sold 134,720 shares on June 24, 2026. The shares were sold at an average price of $100.51, totaling approximately $13.54 million. This was a planned transaction under Rule 10b5-1.

Insider Buying and Selling at Kymera Therapeutics, Inc.

In addition to Booth's sale, Noah Goodman, the Chief Business Officer, transacted 5,000 shares at $114.00 per share on June 25, 2026, as part of a planned sale. Goodman also bought 5,000 shares at $21.05 per share on the same day in an unplanned transaction. Gorjan Hrustanovic acquired 6,068 shares on June 24, 2026, in an unplanned buy.

Other Institutional Activity in Kymera Therapeutics

FMR LLC increased its holdings in Kymera Therapeutics by 2,771,376 shares, bringing its total to 11,699,950 shares worth around $974.49 million. T. Rowe Price Investment Management, Inc. significantly boosted its position by 4,835,252 shares, now holding 5,464,997 shares valued at $455.18 million. Price T Rowe Associates Inc /MD/ slightly reduced its stake by 98,488 shares, ending with 6,060,847 shares valued at about $504.81 million.

Kymera Therapeutics, Inc. Stock Down 1.4%

Shares of NASDAQ:KYMR traded near $99.87 on Friday. Kymera Therapeutics, Inc. has a market capitalization of approximately $8.18 billion. The company is not profitable, as indicated by its negative forward P/E of -22.89. The stock has a 52-week low of $36.65 and a high of $105.00, with a 50-day moving average of $83.06 and a 200-day moving average of $73.55. The company maintains a strong liquidity position with a current ratio of 10.81 and a quick ratio of 10.39.

Analysts Set New Price Targets

On June 25, 2026, BTIG reiterated its buy rating for Kymera Therapeutics, setting a price target of $134. Canaccord Genuity initiated coverage with a buy rating and a $106 target on May 6, 2026. Jefferies assumed coverage with a buy rating and a $110 target on March 16, 2026. The consensus among 21 analysts is a strong buy, with an average target price of $119.19.

About Kymera Therapeutics

Kymera Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing small molecule drugs that degrade disease-causing proteins by leveraging the body's protein degradation system. Key programs include KT-621, an oral STAT6 degrader for atopic dermatitis and other conditions, and KT-579, targeting autoimmune diseases. The company collaborates with Sanofi S.A. for drug development in non-oncology fields.

Bottom Line

Bruce Booth's planned sale of Kymera Therapeutics shares is part of routine insider activity. Investors often watch such transactions for insights, though they don't necessarily reflect the company's current outlook. Kymera remains a focal point for analysts, with recent buy ratings and price targets indicating optimism in its future prospects.